16D0 Dalakas, Marinos - Thomas Jefferson University - Thomas Jefferson University

Marinos C. Dalakas, MD, FAAN

Contact Dr. Dalakas

901 Walnut Street
4th Floor
Philadelphia, PA 19107

(215) 955 -7865
(215) 955-9976 fax

Most Recent Peer-reviewed Publications

  1. HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis
  2. Pathogenesis of immune-mediated neuropathies
  3. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders
  4. Inflammatory muscle diseases inflammatory muscle diseases
  5. Lower extremity peak force and gait kinematics in individuals with inclusion body myositis
  6. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders
  7. Reliability of the adult myopathy assessment tool in individuals with myositis
  8. GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders
  9. Intravenous immunoglobulin in neurology-mode of action and clinical efficacy
  10. Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase
  11. Pathogenesis of immune-mediated neuropathies
  12. IVIg in the chronic management of myasthenia gravis: Is it enough for your money?
  13. Mechanistic effects of IVIg in neuroinflammatory diseases: Conclusions based on clinicopathologic correlations
  14. 7th International immunoglobulin conference: Interlaken leadership awards
  15. Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: A controlled study
  16. 7th International Immunoglobulin Conference: Interlaken Leadership Awards
  17. Are repeated single-limb heel raises and manual muscle testing associated with peak plantar-flexor force in people with inclusion body myositis?
  18. Validity of the single limb heel raise test to predict lower extremity disablement in patients with sporadic inclusion body myositis
  19. Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders.
  20. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study